Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to flexible-dose paliperidone palmitate in schizophrenia after unsuccessful prior antipsychotic treatment
2009-018022-30Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Improved efficacy in non-acute patients transitioned due to lack of efficacy. Started May 2010; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2009-018022-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018022-30.